Cargando…

TP53 Mutations and Clinical Outcome in Chronic Lymphocytic Leukemia: Is a Threshold Still Needed?

Detalles Bibliográficos
Autores principales:	Bomben, Riccardo, Zucchetto, Antonella, Pozzo, Federico, Tissino, Erika, Bittolo, Tamara, Olivieri, Jacopo, Chiarenza, Annalisa, Zaja, Francesco, Del Principe, Maria Ilaria, Rossi, Davide, Gattei, Valter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10079334/ https://www.ncbi.nlm.nih.gov/pubmed/37034005 http://dx.doi.org/10.1097/HS9.0000000000000855

Ejemplares similares

KRAS and RAS-MAPK Pathway Deregulation in Mature B Cell Lymphoproliferative Disorders
por: Vendramini, Elena, et al.
Publicado: (2022)

Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study
por: Bomben, Riccardo, et al.
Publicado: (2023)

P594: THE CXCR4-LOW/CD5-HIGH PROLIFERATIVE FRACTION IS ENRICHED IN BTK MUTATIONS AND ANTICIPATES RELAPSE IN IBRUTINIB-TREATED CLL
por: Pozzo, Federico, et al.
Publicado: (2023)

SF3B1-mutated chronic lymphocytic leukemia shows evidence of NOTCH1 pathway activation including CD20 downregulation
por: Pozzo, Federico, et al.
Publicado: (2020)

Multiple Mechanisms of NOTCH1 Activation in Chronic Lymphocytic Leukemia: NOTCH1 Mutations and Beyond
por: Pozzo, Federico, et al.
Publicado: (2022)

S143: NATURAL CLONAL EVOLUTION OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH BIMODAL CD49D EXPRESSION REVEALS CD49D PLASTICITY
por: Tissino, Erika, et al.
Publicado: (2023)

Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application
por: Pozzo, Federico, et al.
Publicado: (2013)

P606: MEASUREMENT OF INTRACLONAL DIVERSIFICATION REFINES THE PROGNOSTIC IMPACT OF IGHV MUTATIONS IN CLL
por: Vit, Filippo, et al.
Publicado: (2023)

An Updated Perspective on Current Prognostic and Predictive Biomarkers in Chronic Lymphocytic Leukemia in the Context of Chemoimmunotherapy and Novel Targeted Therapy
por: Cohen, Jared A., et al.
Publicado: (2020)

KRAS, NRAS, and BRAF mutations are highly enriched in trisomy 12 chronic lymphocytic leukemia and are associated with shorter treatment-free survival
por: Vendramini, Elena, et al.
Publicado: (2019)

Impaired nodal shrinkage and apoptosis define the independent adverse outcome of NOTCH1 mutated patients under ibrutinib therapy in chronic lymphocytic leukemia
por: Del Poeta, Giovanni, et al.
Publicado: (2020)

The SIRT1/TP53 axis is activated upon B-cell receptor triggering via miR-132 up-regulation in chronic lymphocytic leukemia cells
por: Dal Bo, Michele, et al.
Publicado: (2015)

Combined analysis of IGHV mutations, telomere length and CD49d identifies long-term progression-free survivors in TP53 wild-type CLL treated with FCR-based therapies
por: Pepper, Andrea G. S., et al.
Publicado: (2021)

Integrin Signaling Shaping BTK-Inhibitor Resistance
por: Polcik, Laura, et al.
Publicado: (2022)

Heterogeneity of TP53 Mutations and P53 Protein Residual Function in Cancer: Does It Matter?
por: Monti, Paola, et al.
Publicado: (2020)

Potential therapeutic role of antagomiR17 for the treatment of chronic lymphocytic leukemia
por: Dereani, Sara, et al.
Publicado: (2014)

P597: XPO1 MUTATIONS IDENTIFY EARLY STAGE CLL CHARACTERIZED BY SHORTER TIME TO FIRST TREATMENT AND ENHANCED BCR SIGNALING
por: Talotta, Donatella, et al.
Publicado: (2023)

VLA-4 Expression and Activation in B Cell Malignancies: Functional and Clinical Aspects
por: Härzschel, Andrea, et al.
Publicado: (2020)

Still no flying cars
por: Petsko, Gregory A
Publicado: (2003)

Vaccine hope is still alive
por: Wilson, Clare
Publicado: (2020)

P608: THE EXPRESSION OF CYTOR LNCRNA HAS POOR PROGNOSTIC VALUE IN CLL PATIENTS AND IS ASSOCIATED WITH MICROENVIRONMENTAL STIMULI.
por: Hernández, Lluís, et al.
Publicado: (2023)

Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia
por: Tissino, Erika, et al.
Publicado: (2018)

Antitumor Effects of PRIMA-1 and PRIMA-1(Met) (APR246) in Hematological Malignancies: Still a Mutant P53-Dependent Affair?
por: Menichini, Paola, et al.
Publicado: (2021)

Cost-effectiveness thresholds or decision-making threshold: a novel perspective
por: Sun, Lihua, et al.
Publicado: (2023)

TP53 Mutations in Acute Myeloid Leukemia: Still a Daunting Challenge?
por: Molica, Matteo, et al.
Publicado: (2021)

Prognostic impact of ZAP-70 expression in chronic lymphocytic leukemia: mean fluorescence intensity T/B ratio versus percentage of positive cells
por: Rossi, Francesca M, et al.
Publicado: (2010)

Proper Authentication of Ancient DNA Is Still Essential
por: Eisenhofer, Raphael, et al.
Publicado: (2018)

Predicting extubation success: still a conundrum?
por: Ferguson, Kristin N., et al.
Publicado: (2022)

Why we still need a pandemic treaty
por: Hannon, Elliot, et al.
Publicado: (2022)

Surface-antigen expression profiling of B cell chronic lymphocytic leukemia: from the signature of specific disease subsets to the identification of markers with prognostic relevance
por: Zucchetto, Antonella, et al.
Publicado: (2006)

Adult-onset Still's disease following COVID-19 vaccination
por: Leone, Flavia, et al.
Publicado: (2021)

Genetic discrimination still casts a large shadow in 2022
por: Joly, Yann, et al.
Publicado: (2022)

First manifestation of adult-onset Still's disease after COVID-19
por: Bamidis, Anna D, et al.
Publicado: (2021)

Insulin at 100: still central in protein-based therapy for chronic disease
por: Kurtzhals, Peter, et al.
Publicado: (2021)

Unafraid healthcare providers are still listening: Abortion Care Post-Roe
por: Sullivan, Margaret M.
Publicado: (2022)

Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
por: Tesio, Melania
Publicado: (2023)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

TP53 Co-Mutational Features and NGS-Calibrated Immunohistochemistry Threshold in Gastric Cancer
por: Yu, Ruili, et al.
Publicado: (2021)

Is nanomedicine still promising?
por: Peiris, Pubudu M., et al.
Publicado: (2011)

Adult-onset Still's disease after mRNA COVID-19 vaccine
por: Magliulo, Daniel, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qtcik0ur0v4h5tobnr7rhn58e7